Stopping Disease-Modifying Therapy in Nonrelapsing Multiple Sclerosis
Author:
- 1 January 2017
- journal article
- Published by Consortium of Multiple Sclerosis Centers in International Journal of MS Care
- Vol. 19 (1) , 11-14
Abstract
Background: Current disease-modifying therapies (DMTs) are of benefit only in people with relapsing forms of multiple sclerosis (RMS). Thus, safely stopping DMTs in people with secondary progressive MS may be possible. Methods: Two groups of patients with MS were studied. Group A consisted of 77 patients with secondary progressive MS and no evidence of acute central nervous system inflammation for 2 to 20 years. These patients were advised to stop DMTs. Group B consisted of 17 individuals with RMS who stopped DMTs on their own. Both groups were evaluated at treatment cessation and for a minimum of 1 year thereafter. Multiple variables were assessed to determine those that predicted recurrent acute disease. Results: Nine patients in group A (11.7%) and ten patients in group B (58.8%) had recurrent acute disease, almost always within 1 to 2 years of stopping treatment. The only variable of significance in group A distinguishing stable and relapsing patients was age (P = .0003), with relapsing patients being younger. Group B patients were younger and had significantly lower Expanded Disability Status Scale scores than group A, with no significant differences in age between relapsed and stable patients. Conclusions: The DMTs can be stopped safely in older patients with MS (≥7 decades) with no evidence of acute disease for 2 years or longer, with an almost 90% probability of remaining free of acute recurrence. The high proportion of untreated patients with RMS experiencing recurrent acute disease is consistent with published data.Keywords
This publication has 13 references indexed in Scilit:
- Relapses and disability accumulation in progressive multiple sclerosisNeurology, 2015
- MS disease activity in RESTORENeurology, 2014
- Immunology of Relapse and Remission in Multiple SclerosisAnnual Review of Immunology, 2014
- Interferon beta for secondary progressive multiple sclerosisCochrane Database of Systematic Reviews, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?Multiple Sclerosis Journal, 2009
- The relation between inflammation and neurodegeneration in multiple sclerosis brainsBrain, 2009
- Multiple sclerosisThe Lancet, 2008
- The Immunology of Multiple SclerosisSeminars in Neurology, 2008
- Increased disability and MRI lesions after discontinuation of IFN-beta-1a in secondary progressive MSActa Neurologica Scandinavica, 2005